SKYE

SKYE BIOSCIENCE INC

SKYE·83086J200·US·Common Stock·Healthcare - Biotechnology-Activist

SKYE (SKYE BIOSCIENCE INC) is held by 27 institutional investors as of Q1 2026. Largest holders: BAKER BROS. ADVISORS LP ($968,144), VANGUARD CAPITAL MANAGEMENT LLC ($470,141), BlackRock, Inc. ($175,855). Net institutional sentiment: Mixed.

27
Holders
Avg rating(7 Elite)
$2.2M
Total Value
42% (35)
Fund Consensus
11 buying - 15 selling
SKYESmart Money Verdict
View all
Held by 27 funds
7 elite
Who's Trading
Activist5V5AM Partners VII, LLC29.2%Dec 16, 2025
Insider5L5AM Partners VII, LLCSell $561KAug 22, 2025
InsiderSJSchwab Andrew J.Sell $561KAug 22, 2025
InsiderSJSchwab Andrew J.Sell $22KAug 22, 2025
Insider5L5AM Partners VII, LLCSell $22KAug 22, 2025
InsiderSJSchwab Andrew J.Sell $209KAug 21, 2025
Insider5L5AM Partners VII, LLCSell $209KAug 21, 2025
Insider5L5AM Partners VII, LLCSell $8KAug 21, 2025
InsiderSJSchwab Andrew J.Sell $8KAug 21, 2025
ActivistSchonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC3.6%Aug 14, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
1.6M(+8.6%)$968,1440.0%-85.78%
27
New
764,457$470,1410.0%-6.76%
37
Increased
286,131(+1.5%)$175,8550.0%-72.51%
16
Increased
277,256(+31.9%)$170,4470.0%-87.37%
20
Decreased
258,200(-32.1%)$158,6900.0%-83.21%
0
New
104,229$64,1010.0%-6.76%
32
Unchanged
75,326$46,2950.0%-90.20%
0
Increased
45,762(+244.4%)$28,1430.0%-44.72%
21
Decreased
40,919(-22.9%)$25,1490.0%-5.48%
0
Decreased
25,684(-50.3%)$15,7850.0%-81.01%
0
Decreased
20,194(-12.7%)$12,4110.0%-5.48%
0
Unchanged
20,142$12,3790.0%-86.18%
0
Decreased
18,089(-14.9%)$11,1170.0%-5.48%
0
Decreased
7,205(-59.3%)$4,4280.0%-40.47%
0
New
4,557$2,8030.0%-6.76%
20
Decreased
2,549(-40.3%)$1,5670.0%-86.67%
0
Unchanged
1,158$7120.0%-5.48%
0
Increased
600(+299x)$3640.0%-8.13%
12
Unchanged
400$2420.0%-5.48%
0
Increased
79(+216.0%)$510.0%-52.45%
12

Showing 1-20 of 35

1 / 2

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used